Cargando…

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease

OBJECTIVE: To determine the performance of 3 circulating markers for the diagnosis and the progression of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA). METHODS: Serum concentrations of 3 circulating markers, lung epithelial-derived surfactant protein D (SPD), chemokine C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avouac, Jérôme, Cauvet, Anne, Steelandt, Alexia, Shirai, Yuichiro, Elhai, Muriel, Kuwana, Masataka, Distler, Oliver, Allanore, Yannick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209254/ https://www.ncbi.nlm.nih.gov/pubmed/32384128 http://dx.doi.org/10.1371/journal.pone.0232978

Ejemplares similares

Relevance of circulating Semaphorin 4A for rheumatoid arthritis response to treatment
por: Avouac, Jérôme, et al.
Publicado: (2023)

Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis
por: Leblond, Agathe, et al.
Publicado: (2018)

Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease
por: Al Tabaa, Omar, et al.
Publicado: (2023)

Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2015)

Retraction Note: Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2023)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models
por: Elhai, Muriel, et al.
Publicado: (2015)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Shirai, Yuichiro, et al.
Publicado: (2021)

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis
por: Boleto, Gonçalo, et al.
Publicado: (2018)

Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity
por: Jodon de Villeroché, Vanina, et al.
Publicado: (2010)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis
por: Desallais, Lucille, et al.
Publicado: (2014)

Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis
por: Cauvet, Anne, et al.
Publicado: (2023)

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
por: Matteson, Eric L., et al.
Publicado: (2023)

Targeting Costimulatory Pathways in Systemic Sclerosis
por: Boleto, Gonçalo, et al.
Publicado: (2018)

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
por: Liang, Minrui, et al.
Publicado: (2022)

Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy
por: Gono, Takahisa, et al.
Publicado: (2022)

Soluble CD163 as a Potential Biomarker in Systemic Sclerosis
por: Frantz, Camelia, et al.
Publicado: (2018)

Regulatory T Cells in Systemic Sclerosis
por: Frantz, Camelia, et al.
Publicado: (2018)

Discrepancy between patient and physician in assessment of global severity in early rheumatoid arthritis
por: Kaneko, Yuko, et al.
Publicado: (2012)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Rheumatoid arthritis-associated interstitial lung disease
por: Solomon, Joshua J, et al.
Publicado: (2012)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis
por: Micheroli, Raphael, et al.
Publicado: (2022)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Interstitial Lung Disease in Rheumatoid Arthritis in the Era of Biologics
por: Picchianti Diamanti, A., et al.
Publicado: (2011)

The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis
por: Cavagna, Lorenzo, et al.
Publicado: (2013)

Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease
por: Jani, Meghna, et al.
Publicado: (2017)

Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease
por: Kim, Yerin, et al.
Publicado: (2023)

Candidate Markers for Stratification and Classification in Rheumatoid Arthritis
por: Bader, Lucius, et al.
Publicado: (2019)

Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis
por: Fukue, Ryosuke, et al.
Publicado: (2022)

Emphysema and Interstitial Pneumonia in Rheumatoid Arthritis
por: Sakai, Fumikazu
Publicado: (2018)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Predicting outcomes in rheumatoid arthritis related interstitial lung disease
por: Jacob, Joseph, et al.
Publicado: (2019)

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models
por: Orvain, Cindy, et al.
Publicado: (2022)

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
por: Meier, C., et al.
Publicado: (2020)

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
por: Kuwana, Masataka, et al.
Publicado: (2021)

Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis
por: Furukawa, Hiroshi, et al.
Publicado: (2021)

A Case of Rheumatoid Arthritis-Associated Interstitial Lung Disease - An Unfortunate Complication of Untreated Rheumatoid Arthritis!
por: Ruggiero, Raffaele A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_987t2ntiq185n5hslvq0o6q8lq